Azenta, Inc. Acquires Ziath, Ltd.
February 3, 2023
Azenta, Inc. (Nasdaq: AZTA) has acquired Ziath, Ltd., a Cambridge, UK–based provider of 2D barcode readers for life sciences laboratory applications. Ziath will join Azenta's Life Sciences Products business (Consumables and Instruments); CEO and co-founder Neil Benn will continue to lead the business, and the deal is expected to be accretive to non-GAAP earnings in FY2023 and GAAP earnings in FY2024.
- Buyers
- Azenta, Inc.
- Targets
- Ziath, Ltd.
- Industry
- Medical Devices
- Location
- Cambridgeshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Azenta Acquires UK Biocentre Limited to Expand European Biorepository Capabilities
March 6, 2026
Healthcare Services
Azenta, via its wholly owned subsidiary Azenta UK Ltd, acquired UK Biocentre Limited for £20.5 million (net of cash), including up to £1.8 million in contingent milestone consideration. The acquisition expands Azenta’s UK and broader European sample management, storage, and high-throughput processing capabilities, with UK Biocentre intended to serve as a European operational hub supporting life sciences customers.
-
Bruker Corporation Acquires ZONTAL Inc.
May 8, 2023
Software
Bruker Corporation has closed the acquisition of ZONTAL Inc., a provider of a GxP-compliant life-sciences data platform, to strengthen Bruker BioSpin's Integrated Data Solutions (IDS) software portfolio. The deal (terms not disclosed) will integrate ZONTAL's vendor-agnostic laboratory and process data management capabilities with Bruker's Mestrelab, Arxspan and Optimal offerings to accelerate digital laboratory transformation for biopharma and life-science customers; ZONTAL expected 2023 revenues of greater than $5 million.
-
AstraZeneca to Acquire EsoBiotec
March 18, 2025
Biotechnology
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.
-
Arranta Bio Acquires Captozyme
November 13, 2019
Biotechnology
Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.
-
Trinity Consultants Acquires Aztec Technologies (and Aztec Process Automation Pvt. Ltd.)
March 14, 2022
Engineering Services
Trinity Consultants has acquired Aztec Technologies in the United States and Aztec Process Automation Pvt. Ltd. in India. The acquisition expands Trinity's engineering and industrial automation capabilities for life sciences clients, integrating Aztec's automation, data analytics, panel design and fabrication expertise with Trinity's life-science engineering solutions.
-
AstraZeneca Acquires Fusion Pharmaceuticals
March 19, 2024
Biotechnology
AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage company developing next-generation actinium-based radioconjugates, for $21.00 per share in cash plus a non-transferable contingent value right that could bring the total to approximately $2.4 billion. The acquisition adds Fusion's pipeline (including FPI-2265 for mCRPC), R&D and manufacturing capabilities in radioconjugates and strengthens AstraZeneca's oncology portfolio and presence in Canada.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.